Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial
新辅助 PD-1 抑制剂（特瑞普利单抗）联合化疗治疗 II-III 期 NSCLC 的安全性和有效性（LungMate 002）：一项开放标签、单组、2 期临床试验
期刊:BMC Medicine
影响因子:7
doi:10.1186/s12916-022-02696-4
Xinsheng Zhu #, Liangdong Sun #, Nan Song #, Wenxin He #, Boxiong Xie #, Junjie Hu, Jing Zhang, Jie Yang, Jie Dai, Dongliang Bian, Haoran Xia, Fenghuan Sun, Anwen Xiong, Jie Luo, Lele Zhang, Huansha Yu, Ming Liu, Hongcheng Liu, Haifeng Wang, Haiping Zhang, Chang Chen, Chunyan Wu, Liang Duan, Yuming
